"Stupid" French finance bill set to add 30-40% to biotech wage costs, says France Biotech
This article was originally published in Scrip
Article 78 of the Finance Bill currently going through the French parliament system will cost research-based French biotechnology companies 30-40% more in increased salaries and will emasculate the advantageous tax status currently enjoyed by Jeunes Enterprises Innovantes (JEI: Young Innovative Companies), according to the French biotechnology industry association, France Biotechnology.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.